



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/083,793	05/22/1998	BRIAN R. MURPHY	17634-000320	4558

7590 07/28/2004

JEFFREY J. KING, ESQ.  
GRAYBEAL JACKSON HALEY LLP  
155 - 108th AVENUE, N.E. SUITE 350  
BELLEVUE, WA 98004-5901

EXAMINER

CHEN, STACY BROWN

ART UNIT PAPER NUMBER

1648

DATE MAILED: 07/28/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b>		<b>Applicant(s)</b>	
	09/083,793		MURPHY ET AL.	
	<b>Examiner</b>		<b>Art Unit</b>	
	Stacy B Chen		1648	

**-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --**

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 24 June 2004.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-94 and 96-143 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-94 and 96-143 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |   |   |
|---|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)                        | 4) <input type="checkbox"/> Interview Summary (PTO-413)                     |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)    | Paper No(s)/Mail Date. _____  |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| Paper No(s)/Mail Date _____   | 6) <input type="checkbox"/> Other: _____                                    |

Art Unit: 1648

## DETAILED ACTION

### *Continued Examination Under 37 CFR 1.114*

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on June 24, 2004 has been entered. Claims 1-94 and 96-143 are pending and under examination.
2. A copy of the originally filed claims submitted by Applicant at the request of the Office is noted with appreciation.

### *Claim Rejections - 35 USC § 102/103*

3. The following rejections are maintained for reasons of record. Applicant's arguments have been carefully considered and addressed below, but fail to persuade withdrawal of the rejections.
  - Claims 1-17, 20, 21, 26, 27, 30, 33-41, 43-50, 52, 54-59, 61-94, 96-116, 118 and 120-143 are rejected under 35 U.S.C. 102(e) as anticipated by, or in the alternative, under 35 U.S.C. 103(a) as obvious over Belshe *et al* (5,869,036, herein, "Belshe"), for reasons of record and in view of following. Claims 5, 8, 9, 41, 45, 46, 50, 55, 58, 86, 87 and 92 are now included in the above rejection. The claims are drawn to limitations of the isolated polynucleotide molecule comprising a PIV genome/antigenome with a heterologous PIV sequence from HPIV1, 2, 3, BPIV or MPIV, wherein the polynucleotide further

Art Unit: 1648

comprises a sequence from measles virus, such as a sequence encoding the HN and F proteins. Also claimed are subviral particles, and separate expression vectors for the genes encoding the N, P and L proteins of PIV. Belshe teaches the incorporation of measles virus (HN and F proteins) into chimeric PIV viruses (col. 18, lines 8-10). Also taught are separate expression plasmids for N, P and L genes (col. 15, lines 11-12). Regarding the subviral particle, one of ordinary skill in the art would have expected the production of subviral particles in Belshe's method because of the nature of viral processing and assembly through the host cell.

- The rejection of claims 51 and 53 under 35 U.S.C. 103(a) as obvious over Belshe is maintained for reasons of record.
- The rejection of claims 18, 19, 28 and 29 under 35 U.S.C. 102(e) as anticipated by Belshe, or in the alternative, under 35 U.S.C. 103(a) as obvious over Belshe in view of Stokes *et al* (*Virus Research*, 1993) is maintained for reasons of record.
- The rejection of claims 22-25, 31, 32, 42, 60, 117 and 119 under 35 U.S.C. 103(a) as obvious over Belshe in view of Conzelmann (*J. Gen. Vir.*, 1996) is maintained for reasons of record.

4. (*New Rejection*) Claims 91-143 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-67 of copending Application No. 10/030,544. Although the conflicting claims are not identical, they are not patentably distinct from each other because the copending claims to HPIV/BPIV chimeras are within the scope of the instantly claimed PIV chimeras.

Art Unit: 1648

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

5. In the response filed June 24, 2004, Applicant's substantive arguments are primarily directed to the assertion that the Office failed to critically assess the facts presented in the declaration of Brian R. Murphy under 37 CFR 1.132, filed August 26, 2002. Applicant asserts that the Office failed point out the "opinion testimony" in the declaration. Applicant also addresses the issue of questioning the validity of patented claims. Applicant asserts that the Office is not barred from questioning the validity of a patent claim during interferences and reexaminations. The Office acknowledges that the validity of patented claims is questioned during interferences, reexaminations and other appropriate contexts. Applicant also points out that only the claims of patents are presumed valid. In response, the specification and the **claims** of the Belshe patent are being applied in the art rejections. Therefore, the claims of Belshe are presumed valid, lacking clear and convincing evidence to the contrary, which Applicant has failed to provide.

6. Further, Applicant argues that an anticipatory reference is not only required to show how to make, but also how to use, in order to meet the enablement requirement (Bristol-Myers Squibb v. Ben Venue Laboratories, Inc., 246 F.3d 1368, 1374, 58 USPQ2d 1508, 1512, Fed. Cir. 2001). The court's citation of In re Donohue, 226 USPQ 619 Fed. Cir. 1985, does not support its interjection that an anticipatory reference must show how to make and use to meet the enablement requirement. In re Donohue, 226 USPQ 619 (Fed. Cir. 1985) states that a disclosure

Art Unit: 1648

of a claimed invention in printed publication will not qualify as prior art if it is not enabling, but that it need not actually have been made in order to satisfy the enablement requirement. In re Schoenwald, 22 USPQ2d 1671 (Fed. Cir. 1992) states that an anticipatory reference needs only to describe a compound, not a utility. The MPEP states that a reference is enabling if one of ordinary skill in the art could have made it (MPEP 2121.01). Therefore, all that is required for an anticipatory reference to be enabling is that one be able to make the invention.

7. In response to the assertion that the Office has failed to assess the facts of the declaration, Applicant has failed to point out what facts were overlooked by the Office. In the Office action of November 17, 2003, all of the pertinent points of the declaration were considered and commented on. In response to the assertion that the Office has failed to point out the opinion testimony of Dr. Murphy, the following points of the Murphy declaration relating to the pending rejections are addressed:

- i. Paragraphs 7 and 8 are opinion testimony. The only fact presented in paragraph 7 is that Belshe did not actually produce a PIV from cDNA. In Applicant's arguments submitted June 24, 2004, Applicant argues that there are structural and functional distinctions in the claimed products over the non-recombinant PIV of Belshe. Applicant points to the fact that Belshe never actually made a recombinant PIV from cDNA. Applicant also argues that the actual PIV that Belshe produced is not chimeric, nor infectious. In response, actual reduction to practice is not a requirement for written description or enablement of a reference. Further, Applicant has not pointed out the structural differences between

Art Unit: 1648

Applicant's virus and Belshe's virus – such as different viral proteins, if any. The claims of Belshe are a species of Applicant's broad genus claim 1.

- ii. Paragraph 10 presents the fact that Belshe failed to recover a recombinant PIV from cDNA. Other comments in paragraph 10 are conclusory statements.
- iii. Paragraph 11 presents the fact that the instant application provides an actual reduction to practice of the claimed invention by demonstrating the recovery of PIV from cDNA.  
Actual reduction to practice is not a requirement for written description or enablement.
- iv. Paragraph 12 presents the fact that Belshe performs a complementation assay. It is Applicant's opinion that the lack of a control plasmid to verify Belshe's results would not lead one of skill to have an expectation of success. In response, the lack of a control plasmid is acknowledged, however, the lack of a control plasmid does not materially affect the ability of one of skill to make the claimed invention. A control plasmid would be ideal, however, the lack of one does not constitute clear and convincing evidence that one would not have been able to make the claimed invention.
- v. Paragraph 13 is opinion testimony. Dr. Murphy's comments are simply an interpretation of data and not factual evidence. Statements by Dr. Murphy, such as, "even if the complementation is accepted as authentic, it is of such a low efficiency that its significance is highly doubtful." This type of statement is not clear and convincing evidence that one would not have been able to make the claimed invention. Another example of opinion evidence is "[A]t best, the findings are simply suggestive that the L gene mutations might contribute to some undefined portion of the temperature sensitivity

Art Unit: 1648

of the cp45 virus". Again, the Office considers such a statement to be Dr. Murphy's interpretation of Belshe's results without factual evidence.

- vi. Paragraph 14 presents Dr. Murphy's methodology for verifying attenuation. Despite the fact that Belshe did not perform all the verification tests for attenuation, Belshe's failure to perform them does not materially affect the process of making an attenuated recombinant virus, nor does it mean that one would not have been able to make the claimed invention.
- vii. Paragraphs 15 and 16 present the fact that the sequence of cp45 L gene disclosed in Belshe contained errors and that the complete, correct sequence of cp45 is contained in the instant application. Dr. Murphy points to the fact that major attenuating mutations in PIV3 cp45 are in genes encoding the L, C and F proteins. While the Office recognizes these facts, the instant claims are not commensurate in scope with the arguments. For example, Dr. Murphy states that the teachings of Belshe fail to disclose that there were any attenuating mutations in the F and C genes and that they were useful in cDNA-derived recombinant vaccine viruses. In response, the claims are not entirely drawn to recombinant PIVs having mutations in the F and C genes. Further, Applicant has failed to show that the errors in the sequence would have resulted in an inoperable method or product.
- viii. Paragraphs 17 presents opinion testimony, not based on any facts. Dr. Murphy merely concludes that Belshe fails to describe or enable any chimeric cDNA constructs and methods for recovering them. It is Dr. Murphy's opinion that one would not have had clear teachings or motivation to achieve the claimed invention. Dr. Murphy points to the



Art Unit: 1648

“broad, prophetic and overreaching statements” of Belshe without backing up them up with factual evidence to the contrary. Belshe’s teachings (col. 8, Belshe) may cover a vast diversity of virus capable of being used in Belshe’s method, however, the vast diversity does not automatically render the method non-enabled. (Paragraph 18 and Table 1 summarize the previous paragraphs into Table format.)

- ix. Paragraph 19 presents the fact that the Belshe reference fails to provide an accurate sequence of a wild type PIV virus. Dr. Murphy concludes that because of the errors in the sequence, that one would not have expected a viable virus. However, at the time of Belshe’s invention, it was not yet known that there were errors, so there could not be any negative expectation. Further, even with the errors in the sequence, no one has demonstrated that one cannot recover a recombinant PIV (from the erroneous sequence) commensurate in scope with the claims. Dr. Murphy points out that for nearly seven years after the filing date of Belshe, that Belshe and co-workers have “apparently failed to recover any PIV from cDNA”. In response, a reference is presumed operable until applicant provides facts rebutting the presumption of operability. Since it has not been demonstrated that attempts to prepare the virus were unsuccessful before the date of invention, Dr. Murphy’s assertions are not adequate to show inoperability of Belshe’s method. (See MPEP 2121.02).
- x. Paragraphs 20-24 present facts relating to the recovery of PIV from cDNA. Dr. Murphy concludes that aspects critical to the recovery of PIV from cDNA were not disclosed in Belshe. Paragraphs 25-27 reiterate the importance of Applicant’s findings. In response, the technical aspects of recovery and the discovery of the nuances of PIV production

Art Unit: 1648


from cDNA are indeed notable and important. Yet there is no factual evidence that one could not have accomplished the same with Belshe's guidance. Dr. Murphy's conclusions of inadequate written description and enablement of the Belshe reference are based on opinions regarding Belshe's methodology. In short, while Belshe's methodology is lacking in comparison to Applicant's findings, Applicant has not presented clear and convincing evidence to support the assertion that one could not have made the claimed invention.


### *Conclusion*

8. No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Stacy B. Chen whose telephone number is 571-272-0896. The examiner can normally be reached on M-F (7:00-4:30).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James C. Housel can be reached on 571-272-0902. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

  
Stacy B. Chen  
July 21, 2004

  
JAMES HOUSEL  
SUPERVISORY PATENT EXAMINER  
TECHNOLOGY CENTER 1600  
7/26/04